Yishan Wong

Senior Vice President, Chief Medical Officer, Oncology/Hematology and Supportive Care

2017

Lead global CAR-T CD19 immunotherapy of r/r lymphoma/leukemia, cancer patients’ care, cancer drug development and clinical executive team. Lead global clinical trials, medical monitoring, safety monitoring, manage drug induced renal toxicity, cardiac toxicity, hematologic toxicity and liver injuries of individual patients. Lead global clinical development of solid tumors, hematologic tumors and supportive care, Clinical Operations, Regulatory, Biostatistics, Pharmacovigilance, CMC, Imaging, laboratories and Medical Affairs; facilitate interactions with KOLS. Collaborate with Manufacturing functions to support successful trial execution associated project and budget planning and risk management. Lead global CROs, with ICH, FCP guidelines Lead late stage drug trials… • Phase 2 CAR-T therapy of lymphoma and leukemia in USA. Canada, UK, Spain and France • Phase 2 oncolytic virus therapy of patients with EGFR-mutant metastatic lung cancer in USA, EU, • Phase 3- ADC/chemotherapy therapy of post-surgery, relapse/refractory Squamous Cell carcinoma in USA, Canada, India, Japan • Phase 3- Oncolytic Virus Therapy metastatic breast cancer in USA, Canada • Phase 3- Oncolytic Virus Therapy of glioblastoma, USA Awards: • Ministry of Health Fellow, Japan • United Nation Fellow Award • Best Oncologist of USA, 2017 • Best Oncologist of USA, 2011 • Best Clinical Fellow Award: Walter Reed Army Institute of Research and Medical Center, Washington DC , USA

Chief Clinical Officer, Cancer Drug Development; CAR-T immunotherapy

2023

CAR-T cell therapy of lymphoma and leukemia. Highly active T cell therapies for cancer. An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Clinical and safety data review and BLA submission Safety and efficacy of a CAR-T cell treatment targeting CD19, in adult patients with relapsed or refractory B cell Acute Lymphoblastic Leukemia. Pre-BLA meeting with FDA File BLA FDA Inspection readiness

Co-Founder, Chief Medical Officer

2023

Board of Directors Medical Oncology

2022

Vision is to be at the forefront of cancer drug testing and provide personalized medicine testing to each individual suffering from cancer to better their chance of treatment and survival.

Board Members- Scientific & Medical Advisory Board- Oncolytic Virus Therapy

2018

Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer. Systemic enveloped oncolytic virotherapy program targeting all tumor types, including advanced metastatic disease, and the clinical development of Calidi’s CLD-101 (NeuroNova) and CLD-201 (SuperNova) programs. Calidi's systemic enveloped virotherapy program, ImmunoNova, leverages extensive experience in utilizing cells to protect, potentiate and deliver virotherapies. Utilizing an engineered and enveloped vaccinia virus to treat all cancerous tumors.

Chief Physician Safety & Medical Monitor; Leukemia, Lymphoma, and solid tumors clinical trials

2020

Medical and Safety Physician of solid tumors, lymphoma and leukemia global study medical and safety monitoring and Patients Safety Evaluation of Oncology/Hematology/Oncolytic virus Therapeutics. Review Medwatch and CIOMS and support Safety Monitoring Committee. Data review in ARGUS, ajudication, signal detection, risk managemnt. • Phase 3. Oncolytic virus intratumoral therapy of glioblastoma Nivolumab, lirilumab in cisplatin-Ineligible muscle-invasive bladder cancer patients • Phas 3. Venetoclax in combination with obinutuzumab and bendamustine in follicular lymphoma patients • Phase 3. Ixazomib and Ibrutinib in relapsed/refractory mantle cell lymphoma • Phase 3. Bendamustine and Rituximab plus Venetoclax in untreated mantle cell lymphoma • Phase 3. Anti – PD-1, durvalumab, with chemo for treatment of unresectable mesothelioma • Phase 3. metastatic breast with oncolytic virus therapy combination with anti-PD-1 & paclitaxel • Phase 3. Gilteritinib vs midostaurin in FLT3 mutated acute myeloid leukemia

Clinical Officer Oncology- Consultant

2024

Director Board Of Directors Oncology

2019

Creating Tomorrow's New Cancer Treatment

Founder - Board Member,

2017

Establishing a registry of multiple myeloma -Oncolytic virus trappy of solid tumors -CAR-T therapy of lymphoma and leukemia -Oncology Forum provides global clinical trials; a unique strategy for identification of patients per clinical study protocols, increase the fastest patients’ recruitment and fast regulatory approval. Bring drugs of an Unmet Medical Needs to the patients and specializes in ADC Therapy, CAR-T Therapy, Oncolytic Virus Therapy. -Antibody-drug conjugates as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic (anticancer) payload or drug. Antibody-drug conjugates are examples of bioconjugates and immunoconjugates. Multiple myeloma is the second most common hematologic malignancy worldwide. The treatment of patients with multiple myeloma has changed in the past decade.

Chief Medical Officer, Oncology and Hematology

2022 - 2023

Oncology, Hematology and Supportive Care of metastatic cancer patients.... Develop immunotherapy for metastatic cancer patients’ own T-cells therapy against cancer, as an alternative to chemotherapy, radiation or radical surgery; Lymphoma, Leukemia, Myelodysplastic Syndrome (MDS) and solid tumors; triple negative Breast cancer • Leading global Phase 1 – 3, registration, 3b and 4 clinical trials, medical monitoring, safety monitoring, AEs/SAEs signal detection, risk management, imaging management, and data review. • Lead global cell therapy of leukemia lymphoma and myelodysplastic syndromes. Responsible for phase 3 study of bone marrow transplant in patients undergoing to transplant in leukemia, lymphoma patients and MDS patients/ • Responsible for successful clinical, medical, operation, regulatory, safety, pts recruitment, CRO and regulatory agency communications